Global Principles on Incentivizing Antibiotic R&D
Now, more than ever, we need to accelerate the creation of a vibrant and sustainable innovation ecosystem to support R&D for new antibiotics and other antimicrobials addressing pathogens prioritized by leading public health bodies.
In this position paper we outline what the innovative pharmaceutical industry believes are priority policy actions for governments to take to enable sustainable innovation against AMR.
Related news and resources
WHO EMRO RC71: Promoting collaborative action to accelerate the response to antimicrobial resistance in the Eastern Mediterranean Region
On 16 October 2024 in Doha, Qatar, IFPMA delivered a statement at the 71st session of the WHO EMRO Regional Committee on Promoting collaborative action to accelerate the response to antimicrobial resistance in the Eastern Mediterranean Region.
Read moreStatement from IFPMA at UN HLM on AMR 2024
On 26 September 2024, IFPMA submitted the following statement from the floor at the UN High-Level Meeting on AMR. Eight years after the first ever AMR high-level meeting we find ourselves at the precipice of turning the tide. The pharmaceutical industry heard the call to action at the first high-level meeting, and through establishing the...
Read moreSustainable access to effective antibiotics
In a new position paper, IFPMA explores some of the challenges in ensuring access to safe and quality-assured antibiotics and propose a set of policy changes for consideration.
Read more